Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore has closed a $9.3M registered direct offering and concurrent private placements. The offering includes 225,000 pre-funded warrants and 112,500 common stock warrants sold to institutional investors, plus 1,208,310 shares and 604,150 warrants sold in separate private placements. Each pre-funded warrant was priced at $6.43, exercisable at $0.001 per share, while shares were priced at $6.43 each. The total gross proceeds are $9.3M, with $5.645M from company directors and officers. Funds are earmarked for sales, marketing, working capital, and general purposes. CEO Dan Goldberger highlights strong revenue momentum and operational leverage, expecting positive cash flow by 2025.
ElectroCore announced a $9.3 million registered direct offering and concurrent private placements. The company will issue pre-funded warrants and common stock shares to institutional and accredited investors. Each share is priced at $6.4925, and accompanying warrants will be exercisable at $6.43 per share for five years. The proceeds will support sales, marketing, working capital, and general corporate activities. The transactions include significant investments from company directors and officers amounting to $5.645 million. The completion of these offerings is expected by June 5, 2024, pending customary closing conditions.
electroCore, Inc. (Nasdaq: ECOR) announced record first quarter 2024 net sales of $5.4 million, a 96% increase over first quarter 2023. The company launched Truvaga Plus, a direct-to-consumer mobile app-enabled product for general wellness. Gross profit for Q1 2024 was $4.6 million with a gross margin of 84%. Operating expenses were $8.4 million with a decrease in R&D expenses and an increase in sales and marketing investments. GAAP net loss improved to $3.5 million, or $0.53 per share, compared to $5.9 million in Q1 2023. Adjusted EBITDA net loss was $3.1 million, down from $5.1 million in Q1 2023. Cash, cash equivalents, and restricted cash as of March 31, 2024, totaled approximately $8.1 million.
electroCore, Inc. announced that Donald Melnikoff joined as SVP, Engineering, Regulatory, and Compliance, with an inducement grant of 10,000 RSUs. The RSUs were granted under NASDAQ Listing Rule 5635(c)(4) and will vest over three years.
electroCore, Inc. (Nasdaq: ECOR) will announce its first quarter financial results on May 8, 2024, after the market closes. The company, specializing in bioelectronic medicine and wellness, will hold a conference call to discuss the results and answer questions.
electroCore, Inc. (NASDAQ: ECOR) announced positive results from its recent Truvaga Plus consumer study, showing improvements in sleep, focus, stress, energy, and mood. 82% felt calmer, 82% mentally healthier, 77% more alert, 77% more relaxed, 74% slept better, 74% mood improved, and 67% had more energy. Users reported between 30 mins to 2+ hours of additional sleep per night. 87% expressed interest in continuing the product for ongoing wellness benefits.
Summary not available.
Summary not available.
Summary not available.
Summary not available.